The dose-dependent macular thickness changes assessed by FD-OCT in patients with retinitis pigmentosa treated with ciliary neurotrophic factor

Suman Pilli, Robert Zawadzki, David G. Telander

Research output: Contribution to journalArticle

3 Scopus citations


PURPOSE: To evaluate the effect of intravitreal ciliary neurotrophic factor (CNTF) implant on mean macular thickness (MMT) in eyes with retinitis pigmentosa using high-resolution Fourier domain optical coherence tomography imaging. METHODS: A cohort of 8 patients (CNTF-3: n = 5; CNTF-4: n = 3) enrolled in Neurotech sponsored Phase 2 clinical trial underwent Fourier domain optical coherence tomography imaging. A ≥3% change in MMT from baseline or fellow eye was considered as a measurable change. RESULTS: Two patients enrolled in the CNTF-3 study received low-dose implant. At 18 months, a change in MMT from -4.47 μm to 6 μm from baseline was noted. Six patients received high-dose implant (CNTF-3: n = 3; CNTF-4: n = 3). In CNTF-3 group, 1 eye showed an increase in MMT by 19.25 μm (+7.6%) from baseline at 18 months. In CNTF-4 group, 1 eye had an increase in MMT of 27.08 μm (+11%) from baseline at 30 months; second eye had increase in MMT of 31.36 μm (+12%) from contralateral eye. Amongst these 3 responsive high-dose implant eyes, overall thickening of the retina could not be attributed to any specific retinal layer. CONCLUSION: A heterogeneous dose-dependent response on MMT was noted in eyes treated using intravitreal CNTF implant for retinitis pigmentosa. We recommend corroboration of our findings with Neurotech sponsored clinical trial results.

Original languageEnglish (US)
Pages (from-to)1384-1390
Number of pages7
Issue number7
StatePublished - Jan 1 2014



  • ciliary neurotrophic factor
  • encapsulated cell implant
  • Fourier domain optical coherence tomography
  • mean macular thickness
  • retinitis pigmentosa

ASJC Scopus subject areas

  • Ophthalmology

Cite this